Archive for the ‘Cancer’ Category

Ricki
McCarroll

Ladies…You Know Lung Cancer Kills Right?

Wednesday, November 16th, 2011

From a girl who came from the West Coast where the ban of smoking cigarettes in work places was enacted in January 1995 and banned in restaurants three years later, it was a shock to move to the D.C. area and find you could still smoke indoors in some establishments directly outside The District.

My doe-eyed, granola crunching, outdoorsy, non-smoking California self was definitely taken aback at the amount of smokers around me. Even some two and a half years later, it still shocks me on my morning commute to find myself walking behind someone to the Red Line (D)Re(a)d Line who has a cigarette in their hand at 7:30 in the morning.

Naturally, with a health communicator’s strategic mind, I began to tally the amount of men and women I witnessed lighting up during my morning jaunts to work between the hours of 7:30 and 9:00 a.m.

My findings? Interestingly enough, the majority of the people I witnessed were women around the ages of 30-55 strutting in pencil skirts and pumps with a lit cigarette balancing in their hand. To be frank, I was shocked when I tallied the numbers. Really, ladies? After all the facts we know about tobacco?

(more…)

Tags: , , , ,

 
John
Seng

In Memoriam: Dr. Bruce Dan, Medical Newsmaker and Friend

Monday, September 12th, 2011

This past Tuesday evening, my friend Bruce Dan passed away after a lengthy battle with acute myelogenous leukemia (AML), a fairly rare blood and bone marrow cancer. He had been receiving treatment at Johns Hopkins over the past year-and-a-half. During this last journey, he persisted in his passion: story-telling in health care. Except this time, he was the subject. I was introduced to Dr. Bruce B. Dan in the mid-1990s by another friend and former boss, Ken Rabin.

At the time, Ken knew Bruce to be an outstanding media trainer, and it was Bruce’s unique brand of health care media counseling skills that I relied upon over a stretch of more than 15 years. For real “heavy lifting,” in other words, when we figured we would need a double shot of TLC to render articulate the driest medical expert or bombastic pharmaceutical company executive, we called in Bruce.

During any session, Bruce kicked things off with his characteristic big smile, and quiet, engaging style that within minutes put everyone in the room at ease. The man would roll onward, keeping one step ahead with anecdotes, witticisms or piercing questions as he led captive audiences through his training sessions, usually flanked by a medium-sized stack of VHS tapes he used to depict horrific and then good examples of television interview behavior. (Clients always got to keep their own tapes.)

Anytime I called on Bruce, I always tried to carve out extra time with him, to learn from his experiences and get his feedback on my business situations or ideas. Bruce was generous.

Not only did he sincerely care about your point of view, and in his patient style give you all the time you needed, he demonstrated the very best in teaching skills: You learned without even realizing it, Bruce was knowledgeable, interesting and persuasive.

(more…)

Tags: , , ,

 
Ricki
McCarroll

FDA beats out European Counterpart in Oncology Drug Approval

Thursday, June 16th, 2011

The FDA is proving to be a top contender in the international space in its efforts to fight the battle on the Big C, yes we’re talking cancer.

Source: Friends of Cancer Research Study

A new study released online today by Friends of Cancer Research in Health Affairs reports that the U.S. Food and Drug Administration (FDA) has a faster approval rate for oncology drugs than their European counterpart agency, the European Medicines Agency (EMA).

The study was held over a seven year period beginning 2003 through 2010. Authors Samantha A. Roberts, Jeff D. Allen, and Ellen V. Sigal investigated 35 drugs going through approval process in both markets and compiled their results in an eight-page report complete with graphics and pull quotes.

FDA v. EMA Stats

  • 35 drugs were investigated
  • FDA approved 32 oncology drugs while the EMA approved only 26
  • In addition, FDA’s approval for said drugs was over 31 percent more time efficient that the EMA

Statistically speaking, the approval ratio is less than one.

Finding the data

Authors of the study utilized public data bases on the FDA and EMA websites to conduct their research. Drugs used in the study are direct oncology treatments, drugs related to “supportive care” such as pain relievers and anti-nausea medications were omitted in their findings.

Check it Out

The Friends of Cancer Research study is currently available online and will be available in the July issue of Health Affairs.

What’s the spark under the FDA?

Tags: , , , , ,

 
Anthony
LaFauce

The Malaria Conversation on a Global Scale & What it Means for Communicators

Monday, May 23rd, 2011

With smart phones and Twitter at the ready, the first annual International Healthcare Social Media Summit kicked-off at 9:00 am EST on May 18th in Washington, D.C.

Spectrum’s own John Seng welcomed all attendees, virtual and physical, including GLOBALHealthPR partners from over seven countries and introduced the four panelists: Aurora PR‘s Neil Crump and Aaron Pond (UK) , PR Partners‘ Paola de la Barreda (Mexico) and Spectrum’s Anthony LaFauce.

Panelists presented data found in an 11 country, cross-cultural case study pertaining to the malaria pandemic and the evolving use of social media as an outreach resource. You can watch the event start to finish below.


(more…)

Tags: , , , ,

 
John
Seng

A Never-Smoker With Lung Cancer, And The Point Is…?

Tuesday, May 17th, 2011

The next time you hear that a friend of a friend was just diagnosed with lung cancer, you’re bound to wonder privately or out loud: Was he a smoker or not?

It’s only natural. We’re terrified of cancer, and especially, cancers such as lung cancer which are diagnosed usually in late stage, and oftentimes too late to really do much about it. So we all must hear what we need to hear that, yes, this person was or still is a smoker. Phew! We can again comfortably assign blame to some poor soul who should have known better or couldn’t muster the willpower to quit in time. And we think, I don’t smoke, so I’m innocent.

But increasingly we hear from multiple quarters that non-smokers and never-smokers also get lung cancer. In fact, approximately 10 percent of all lung cancer is diagnosed in persons who never smoked. That inconvenient reality surprises a lot of people. In other words, someone who didn’t have it coming to them just got really bad news, despite his or her good behavior, unlike those weak and irresponsible smokers. Some lung cancer advocates report this aberrance, in an attempt to add accurate perspective on the disease. Even more important, researchers are now investigating the differences between tumor types in never-smokers vs. smokers, and why women never-smokers bear a greater burden of disease.

But here’s a radical notion for you, one that I recently suggested to a group of lung cancer advocates gathered in Denver by the National Lung Cancer Partnership: Lung cancer is 100 percent a disease of innocents. I repeat, innocents.

I put forth the proposition that the lifelong female smoker diagnosed with lung cancer is no more “to blame” for her disease than another woman diagnosed with breast cancer. Here’s why. Tobacco use most often begins in our teen years. Raise your hand if you never did anything stupid as a 14-year old. The Army and Navy once distributed cigarettes free to hundreds of thousands of men to help them cope with battle stress. Tobacco companies handed out free samples on college campuses. I once found a copy of an ad for Lucky Strikes that depicts a doctor extolling the virtues of smoking. The best part is, the ad ran in a 1940s edition of The Journal of the American Medical Association. I framed the ad for my office.

(more…)

Tags: , , , , , , ,

 
Spectrum

Cancer Researchers Get Down To Business To Save Lives

Tuesday, May 10th, 2011

Imagine you’re a cancer researcher. In the lab, you’re up to your elbows testing how cancer cell lines react to different drug combinations – hoping that all your long hours and hard work in the Petri dish will result in a successful treatment you can deliver to the grandparent, soccer mom, coach or even 9-year-old little league player you see in the clinic.

What if along your road to oncology alchemy, you uncover a novel approach to treat your patient’s cancer with another compound that’s shown success in other diseases. It should be simple enough to get access to this compound and begin testing, right?

In actuality, the process of drug co-development is a lot more complex than that. Breast cancer researcher and clinical investigator Dr. Bhuvaneswari Ramaswamy, of The Ohio State University Comprehensive Cancer Center, breaks down how this process affects her and her patients in the video below.

(more…)

Tags: , , , ,